The patient subsequently underwent six cycles of chemotherapy combined with immunotherapy, including 400 mg albumin-bound paclitaxel (ab-paclitaxel) i.v. on day 1, 600 mg carboplatin i.v. on day 1, and 1500 mg durvalumab (a programmed death-ligand 1 (PD-L1) inhibitor) i.v. on day 1, administered every 21 days for LS-SCLC. The gene discussed is CD274; the disease is small cell lung carcinoma.